环丙烷丙胺 | 5648-88-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 环丙烷丙胺
• 英文名称: 3-cyclopropylpropylamine
• 英文别名: 3-cyclopropylpropan-1-amine
• CAS: 5648-88-4
• 化学式: C₆H₁₃N
• mdl: MFCD09912941
• 分子量: 99.1759
• InChiKey: FESRYVBBESMTNR-UHFFFAOYSA-N

物化性质

• 沸点：
  117.0±8.0 °C(Predicted)
• 密度：
  0.893±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  7
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921300090

反应信息

• 作为反应物：
  描述：

  环丙烷丙胺 、 6-[4-(2-trifluoromethylbenzoyl)-piperazin-1-yl]pyridazine-3-carbonyl chloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridazine-3-carboxylic acid (3-cyclopropylpropyl)amide
  参考文献：
  名称：

  Discovery of Piperazin-1-ylpyridazine-Based Potent and Selective Stearoyl-CoA Desaturase-1 Inhibitors for the Treatment of Obesity and Metabolic Syndrome

  摘要：

  Stearoyl-CoA desaturase-1 (SCD1) catalyzes de novo synthesis of monounsaturated fatty acids from saturated fatty acids. Studies have demonstrated that rodents lacking a functional SCD1 gene have an improved metabolic profile, including reduced weight gain, lower triglycerides, and improved insulin response. In this study, we discovered a series of piperazinylpyridazine-based highly potent, selective, and orally bioavailable compounds. Particularly, compound 49 (XEN103) was highly active in vitro (mSCD1 IC50 = 14 nM and HepG2 IC50 = 12 nM) and efficacious in vivo (ED50 = 0.8 mg/kg). It also demonstrated striking reduction of weight gain in a rodent model. Our findings with small-molecule SCD1 inhibitors confirm the importance of this target in metabolic regulation, describe novel models for assessing SCD1 inhibitors for efficacy and tolerability and demonstrate an opportunity to develop a novel therapy for metabolic disease.

  DOI：

  10.1021/jm301661h
• 作为产物：
  描述：

  2-环丙基乙醇 在 吡啶 、 lithium aluminium tetrahydride 、 硫酸 、 四丁基碘化铵 作用下， 以 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 环丙烷丙胺
  参考文献：
  名称：

  Piperazine derivatives and their use as therapeutic agents

  摘要：

  公开号：

  EP2316827B1

文献信息

• [EN] SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] IMIDAZOLE CARBOXAMIDES SUBSTITUÉS ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：BIAL BIOTECH INVEST INC

  公开号：WO2021055612A1

  公开（公告）日：2021-03-25

  The invention provides substituted imidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

  这项发明提供了替代咪唑羧酰胺及相关化合物，含有这些化合物的组合物，医疗工具包，以及使用这些化合物和组合物治疗患者的医疗障碍，例如癌症、溶酶体贮积症、神经退行性疾病、炎症性疾病等的方法。
• [EN] BICYCLIC HETEROCYCLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF STEAROYL-COA-DESATURASE (SCD)<br/>[FR] DERIVES HETEROCYCLIQUES BICYCLIQUES ET LEUR UTILISATION COMME INHIBITEURS DE STEAROYL-COA DESATURASE (SCD)
  申请人：XENON PHARMACEUTICALS INC

  公开号：WO2006034312A1

  公开（公告）日：2006-03-30

  Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise, for example, administering to a mammal in need thereof a compound of formula (I): where x, y, J, K, L, M, W, V, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

  本发明涉及治疗哺乳动物，优选为人类，中SCD介导的疾病或病况的方法，其中该方法包括，例如，向需要的哺乳动物施用式(I)的化合物，其中x、y、J、K、L、M、W、V、R2、R3、R5、R5a、R6、R6a、R7、R7a、R8和R8a在此处定义。还披露了包含式(I)的化合物的药物组合物。
• Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase
  申请人：Kamboj Rajender

  公开号：US20080167321A1

  公开（公告）日：2008-07-10

  Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, G, J, K, L, M, W, V, R2, R3, R4, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

  本发明揭示了治疗哺乳动物，尤其是人类的SCD介导疾病或症状的方法，其中所述方法包括向需要的哺乳动物施用本发明公式(I)的化合物，其中x、y、G、J、K、L、M、W、V、R2、R3、R4、R5、R5a、R6、R6a、R7、R7a、R8和R8a在此处定义。还公开了包含公式(I)化合物的药物组合物。
• [EN] COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE L'HYPERGLYCÉMIE
  申请人：ATROGI AB

  公开号：WO2017153737A1

  公开（公告）日：2017-09-14

  There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of hyperglycaemia or a disorder characterized by hyperglycaemia, such as type 2 diabetes, wherein X, R1, R2, R3 and n have meanings as provided in the description.

  本文提供了一种式（I）的化合物或其在药学上可接受的盐，用于治疗高血糖或高血糖症状的疾病，如2型糖尿病，其中X，R1，R2，R3和n的含义如描述中所提供。
• [EN] BETA-HYDROXYETHYLAMINES FOR USE IN THE TREATMENT OR PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASES<br/>[FR] BÊTA-HYDROXYÉTHYLAMINES POUR UTILISATION DANS LE TRAITEMENT OU LA PRÉVENTION DES STÉATOSES HÉPATIQUES NON ALCOOLIQUES
  申请人：ATROGI AB

  公开号：WO2019053428A1

  公开（公告）日：2019-03-21

  There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a non-alcoholic fatty liver disease (NAFLD), such as non-alcoholic steatohepatitis (NASH), wherein X, R1, R2, R3 and n have meanings as provided in the description.

  本文提供了一种化合物（I）或其药用可接受盐，用于治疗非酒精性脂肪肝病（NAFLD），如非酒精性脂肪性肝炎（NASH），其中X、R1、R2、R3和n的含义如描述中所提供。